Disease Domain | Count |
---|---|
Neoplasms | 2 |
Infectious Diseases | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Unknown | 1 |
Prophylactic vaccine | 1 |
miRNA | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein(SARS-CoV-2 S protein) | 1 |
TfR1(Transferrin receptor protein 1) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TfR1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Feb 2024 |
Sponsor / Collaborator |
Start Date05 Jan 2024 |
Sponsor / Collaborator |
Start Date27 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PPMX-T003 ( TfR1 ) | Large Granular Lymphocytic Leukemia More | Phase 2 Clinical |
MIRX-002 | Mesothelioma More | Phase 1 |
NCV2SG48 ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |